Loading
A phase 2 trial of PF-08634404 in non-small-cell lung cancer and small-cell lung cancer, run by Pfizer, now recruiting.
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC is a phase 2 interventional study registered as NCT07489066 by Pfizer, with 120 participants planned, started 2026-06-30 and due to reach its primary completion in 2028-07-29. Interventions recorded: PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2. Conditions listed: Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PF-08634404, Pfizer (incl. Seagen), Small-cell lung cancer.
Shares PF-08634404, Pfizer (incl. Seagen), Non-small-cell lung cancer.
Shares PF-08634404, Pfizer (incl. Seagen), Non-small-cell lung cancer.
Shares PF-08634404, Pfizer (incl. Seagen), Small-cell lung cancer, Non-small-cell lung cancer.
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Non-small-cell lung cancer.
Shares PF-08634404, Pfizer (incl. Seagen).
Shares Pfizer (incl. Seagen), Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/